Provision as per the 1/2 yearly. Update to the status of the Contingent Consideration (Earn-outs) • Earn-out 1 Condition: CY2024 revenue: Within 120 days after the end of CY2024, 4DMedical will pay the Sellers an amount equal to four times the incremental revenue growth (over US$3.5 million) of Imbio products in CY2024 from eligible forecasted CY2023 revenue, up to a cap of US$2.5 million of incremental revenue growth for a maximum Earnout payment of US$10 million. Status: 4DMedical recognised 50% (US$5.0m) of Earn-out 1 as part of the acquisition accounting. The conditions to trigger payment of Earn-out 1 were not met. The reduction in 4DMedical's contingent consideration was recognised in the P&L as a Gain on remeasurement of Contingent Consideration Liability as Other Comprehensive Income (AU$7.9m)
4DX Price at posting:
34.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)